<?xml version='1.0' encoding='utf-8'?>
<document id="27692854"><sentence text="N-Arylsulfonyl-α-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity."><entity charOffset="0-35" id="DDI-PubMed.27692854.s1.e0" text="N-Arylsulfonyl-α-amino carboxamides" /></sentence><sentence text="Compound 1 ((4-amino-3,5-dichlorophenyl)-1-(4-methylpiperidin-1-yl)-4-(2-nitroimidazol-1-yl)-1-oxobutane-2-sulfonamido) was discovered to be a 690nM antagonist of human CCR10 Ca2+ flux"><entity charOffset="9-118" id="DDI-PubMed.27692854.s2.e0" text="1 ((4-amino-3,5-dichlorophenyl)-1-(4-methylpiperidin-1-yl)-4-(2-nitroimidazol-1-yl)-1-oxobutane-2-sulfonamido" /></sentence><sentence text=" Optimization delivered (2R)-4-(2-cyanopyrrol-1-yl)-S-(1H-indol-4-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutane-2-sulfonamido (eut-22) that is 300 fold more potent a CCR10 antagonist than 1 and eliminates potential toxicity, mutagenicity, and drug-drug-interaction liabilities often associated with nitroaryls and anilines"><entity charOffset="24-122" id="DDI-PubMed.27692854.s3.e0" text="(2R)-4-(2-cyanopyrrol-1-yl)-S-(1H-indol-4-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutane-2-sulfonamido" /><entity charOffset="296-306" id="DDI-PubMed.27692854.s3.e1" text="nitroaryls" /><entity charOffset="311-319" id="DDI-PubMed.27692854.s3.e2" text="anilines" /><pair ddi="false" e1="DDI-PubMed.27692854.s3.e0" e2="DDI-PubMed.27692854.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27692854.s3.e0" e2="DDI-PubMed.27692854.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27692854.s3.e0" e2="DDI-PubMed.27692854.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27692854.s3.e1" e2="DDI-PubMed.27692854.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27692854.s3.e1" e2="DDI-PubMed.27692854.s3.e2" /></sentence><sentence text=" eut-22 is highly selective over other GPCR's, including a number of other chemokine receptors" /><sentence text=" Finally, eut-22 is efficacious in the murine DNFB model of contact hypersensitivity" /><sentence text=" The efficacy of this compound provides further evidence for the role of CCR10 in dermatological inflammatory conditions" /><sentence text="" /></document>